OXFORD, United Kingdom, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that management will participate in one on one meetings at SunTrust Robinson Humphrey’s 2016 Orphan Drug Day, taking place 23 February 2016 in New York City.
A copy of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) | Tel: +44 (0)1235 443 951 +1 617 225 4455 | ||
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson |
Tel: +44 (0)20 77148 7900 | ||
| N+1 Singer (Broker) Aubrey Powell / Jen Boorer |
Tel: +44 (0)20 7496 3000 | ||
| Peckwater PR (Financial public relations, UK) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk | ||
| MacDougall Biomedical Communications (US media contact) Chris Erdman | Tel: +1 781 235 3060 cerdman@macbiocom.com | ||
-END-
